Sponsors (7)
Want me to put this bill in plain English?
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Provides multi-year additional funding to the National Cancer Institute (NCI) by requiring annual appropriations for fiscal years 2026–2030 equal to 25% of NCI’s FY2022 appropriation, with those funds available until expended and added on top of other NCI resources. Directs the Department of Health and Human Services, working through the FDA, to complete a one-year study on causes of cancer drug shortages (economic drivers, supply chain failures, development/approval delays, and shortages of generics/biosimilars) and to report findings and recommendations to Congress within one year of enactment.
Introduced June 10, 2025 by Brian K. Fitzpatrick · Last progress June 10, 2025
Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House